Timeline ??? for :
"Lead asset xB3 -001 in neuro-oncology funding anticipated via partnership:
• Targets HER2+ breast and gastric cancer and brain metastases
• Worldwide peak revenue potential for the treatment of HER2+ breast cancer estimated at US$3.7 billion
• Potential for accelerated approval
• Partnering anticipated to deliver meaningful near-term catalysts"
Partnering discussions ongoing, taking place at some point in 2021.
Would xB3-001 be in the partner's hands (entirely) while Bioasis pursues other developments in the pipeline?
Koo
